Naviter Wealth LLC Acquires 13,988 Shares of Pfizer Inc. (NYSE:PFE)

Naviter Wealth LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 35.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 52,975 shares of the biopharmaceutical company’s stock after buying an additional 13,988 shares during the quarter. Naviter Wealth LLC’s holdings in Pfizer were worth $1,482,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Gilbert & Cook Inc. boosted its position in Pfizer by 3.8% in the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock valued at $738,000 after buying an additional 945 shares during the last quarter. Los Angeles Capital Management LLC increased its position in Pfizer by 3.1% in the fourth quarter. Los Angeles Capital Management LLC now owns 29,864 shares of the biopharmaceutical company’s stock worth $860,000 after purchasing an additional 899 shares during the period. Barlow Wealth Partners Inc. bought a new stake in Pfizer during the 4th quarter worth about $222,000. Gryphon Financial Partners LLC lifted its position in Pfizer by 43.7% during the 4th quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock valued at $861,000 after purchasing an additional 8,194 shares during the period. Finally, Bogart Wealth LLC boosted its stake in shares of Pfizer by 1.7% in the 4th quarter. Bogart Wealth LLC now owns 268,539 shares of the biopharmaceutical company’s stock valued at $7,731,000 after purchasing an additional 4,543 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $28.30 on Wednesday. The stock has a market cap of $160.36 billion, a PE ratio of -471.67, a price-to-earnings-growth ratio of 1.02 and a beta of 0.69. The stock has a 50-day moving average price of $29.01 and a two-hundred day moving average price of $28.03. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $36.29. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.67 EPS. Equities analysts forecast that Pfizer Inc. will post 2.66 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th were paid a $0.42 dividend. The ex-dividend date of this dividend was Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 5.94%. Pfizer’s payout ratio is currently -2,800.00%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. UBS Group increased their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Barclays raised their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.